Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
MAINZ, Germany, Dec. 22, 2016 -- BioNTech AG, a fully integrated biotechnology company developing truly individualized cancer immunotherapies, today announced that Sean Marett, COO of BioNTech, will be presenting at 35th Annual J.P. Morgan Healthcare Conference that is being held in San Francisco, CA, January 9 – 12, 2017. The presentation is scheduled for Wednesday, January 11th at 9:30 AM Pacific Standard Time. Mr. Marett will provide an overview of the company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recent Nature publications related to its individualized mRNA cancer vaccines and the establishment of a second mRNA production facility at the Company´s headquarters in Germany.
The J.P. Morgan Healthcare Conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends.
About BioNTech AG
BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated and potent treatments for cancer and other diseases. Established by clinicians and scientists the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel bispecific antibody immunomodulators. BioNTech’s clinical programs are supported by an in-house molecular diagnostics unit whose products include MammaTyper® a molecular in-vitro diagnostic kit, marketed under CE and IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is privately held and shareholders include the MIG Fonds, Salvia, and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.
Information about BioNTech is available at www.biontech.com.
For meeting requests or further information, please contact: BioNTech AG Regina Jehle Tel: +49 6131 9084 1273 Email: [email protected] Investors: Stephanie Carrington ICR, Inc. 646-277-1282 [email protected] Media: James Heins ICR, Inc. 203-682-8251 [email protected] European Media & Investors: akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners [email protected] Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68
